newsfilter
← Latest News
GlobeNewswire·

SpringWorks Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

– Achieved $49.3 million in OGSIVEO® (nirogacestat) net product revenue in the third quarter – – Long-term follow-up data from the Phase 3 DeFi trial of nirogacestat in adults with desmoid tumors highlight